TOP TEN perturbations for 39017_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39017_at
Selected probe(set): 203534_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39017_at (203534_at) across 6674 perturbations tested by GENEVESTIGATOR:
glioma study 17 (glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):1.812664Number of Samples:3 / 3
Experimental | glioma study 17 (glioblastoma; A2B5+) |
Oligodendrocyte progenitor cells (OPC) isolated from high grade glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 66 ± 5 years old males. | |
Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
colorectal cancer study 43 (metastase; brain) / colorectal cancer study 43 (metastase; lung)
Relative Expression (log2-ratio):1.794589Number of Samples:2 / 5
Experimental | colorectal cancer study 43 (metastase; brain) |
Metastatic tumor tissue obtained from the brain of patients with primary colorectal adenocarcinoma. | |
Control | colorectal cancer study 43 (metastase; lung) |
Metastatic tumor tissue obtained from the lung of patients with primary colon adenocarcinoma. |
septic shock study 3 (D1; non-survivor) / normal blood sample
Relative Expression (log2-ratio):1.7891388Number of Samples:17 / 22
Experimental | septic shock study 3 (D1; non-survivor) |
Blood samples from patients (non-survivors) collected at day 1 (D1) after the septic shock onset. According to day 28 survival status, patients were classified as non-survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine (1992). The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection). | |
Control | normal blood sample |
Blood samples from healthy subjects. |
F. tularensis study 1 (novicida) / uninfected peripheral blood monocyte sample
Relative Expression (log2-ratio):-1.7690725Number of Samples:4 / 6
Experimental | F. tularensis study 1 (novicida) |
Peripheral blood monocytes infected with the Francisella tularensis subspecies novicida isolate U112 (100 MOI) for 24 hours. | |
Control | uninfected peripheral blood monocyte sample |
Peripheral blood monocytes uninfected. |
colorectal cancer study 43 (metastase; brain) / colorectal cancer study 43 (metastase; liver)
Relative Expression (log2-ratio):1.7667437Number of Samples:2 / 25
Experimental | colorectal cancer study 43 (metastase; brain) |
Metastatic tumor tissue obtained from the brain of patients with primary colorectal adenocarcinoma. | |
Control | colorectal cancer study 43 (metastase; liver) |
Metastatic tumor tissue obtained from the liver of patients with primary colon adenocarcinoma. |
septic shock study 3 (D2; non-survivor) / normal blood sample
Relative Expression (log2-ratio):1.7493668Number of Samples:8 / 22
Experimental | septic shock study 3 (D2; non-survivor) |
Blood samples from patients (non-survivors) collected at day 2 (D2) after the septic shock onset. According to day 28 survival status, patients were classified as non-survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine (1992). The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection). | |
Control | normal blood sample |
Blood samples from healthy subjects. |
oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample
Relative Expression (log2-ratio):-1.7305965Number of Samples:3 / 3
Experimental | oncolytic herpes simplex virus study 2 |
Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours. | |
Control | mock infected peripheral nerve sheath tumor (S462) cell sample |
Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours. |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary)
Relative Expression (log2-ratio):-1.7105932Number of Samples:6 / 2
Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, synovial sarcoma, spindle cell of the soft tissue (subcutaneously implanted). | |
Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, liposarcoma, well differentiated type of the soft tissue (subcutaneously implanted). |
septic shock study 3 (D3; non-survivor) / normal blood sample
Relative Expression (log2-ratio):1.7074261Number of Samples:9 / 22
Experimental | septic shock study 3 (D3; non-survivor) |
Blood samples from patients (non-survivors) collected at day 3 (D3) after the septic shock onset. According to day 28 survival status, patients were classified as non-survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine (1992). The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection). | |
Control | normal blood sample |
Blood samples from healthy subjects. |
glioma study 17 (small cell glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):1.6642265Number of Samples:2 / 3
Experimental | glioma study 17 (small cell glioblastoma; A2B5+) |
Oligodendrocyte progenitor cells (OPC) isolated from high grade small cell glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 56 ± 3 years old males. | |
Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |